Navigation Links
A comparative medicine study by Penn vet identifies a new approach to combat viral infections
Date:11/9/2012

PHILADELPHIA When a virus such as influenza invades our bodies, interferon proteins are among the first immune molecules produced to fight off the attack. Interferon can also play a role in suppressing tumor growth and the effects of autoimmune diseases, and doctors may use an artificial form of interferon to treat patients with certain cancers or multiple sclerosis. But even this approach sometimes fails when patients' bodies reject the foreign interferon or growing resistant to its effects.

A study by scientists from the University of Pennsylvania School of Veterinary Medicine offers a new strategy for enhancing the effects of interferon in fighting off infection. The research suggests that, by targeting a particular molecule in the interferon signaling pathway, specially designed drugs may be able to boost the activity of a person's own interferon, augmenting the immune system's fight against viruses. It's possible that the same drugs might also be effective against some types of cancer and certain autoimmune conditions.

Serge Fuchs, a professor of cell biology in Penn Vet's Department of Animal Biology and director of the School's Mari Lowe Comparative Oncology Center, was the senior author on the paper published in the Proceedings of the National Academy of Sciences.

"The practical significance of our study is a demonstration of the ability to use emerging pharmaceuticals to reactivate an individual's own interferon or to use a reduced dose to get the same effect," Fuchs said.

Christopher Carbone and Hui Zheng of the Department of Animal Biology and John Lewis and Alexander Reiter of the Department of Clinical Studies played leading roles in the study. Additional Penn Vet collaborators were Sabyasachi Bhattacharya, Paula Henthorn and Kendra Bence. Zhong-Yin Zhang of Indiana University School of Medicine and Darren Baker of Biogen Idec also contributed.

The research would have been impossible without the team's comparative-medicine approach, in which they examined the effects of activating the interferon pathway in both human cells and in cats affected by a naturally occurring disease. Mice would normally be the model organism of choice for such a study, but they lack a molecular element of the interferon pathway that humans and cats share.

"Mice are very convenient, but they may not always recapitulate human diseases that well," Fuchs said. "Veterinary diseases happen naturally, and they provide a less convenient but a more truthful recapitulation of the human situation."

Interferon fights viruses by binding to an interferon receptor on cells, triggering a cascade of other molecular events and leading to the production of proteins that prevent viruses from reproducing or that stimulate other immune responses. But because too much interferon can harm the host's body, this signaling cascade has a built-in brake: Using a separate molecular pathway, interferon triggers the body's cells to remove its own receptor, so the immune system attack doesn't go on indefinitely.

"It's very important to understand what regulates the responsiveness of cells to interferon, and a major factor is the levels of cell-surface receptors," Fuchs said.

Although the researchers' investigations of these pathways led them to identify a target for improving the body's virus-fighting ability, they didn't set out to discover a drug. Rather, they were attempting to solve a paradox of cell biology.

The paradox rests on the fact that many steps in the interferon-signaling pathway involve adding a molecule of phosphate to proteins in the cascade. Interferon itself promotes the addition of phosphate onto the interferon receptor, yet previous evidence suggested that the receptor resisted being removed by the cell if it had phosphate added. Given that interferon does in fact trigger the removal of its own receptor, the research team hypothesized that another enzyme must be at work in the pathway to remove the phosphate molecule from the receptor so it could be consumed by the body's cells to ramp down the immune-system response to viruses.

Performing a screening for this putative enzyme, they identified protein tyrosine phosphatase 1 B (PTP1B) as a likely candidate. In a series of experiments, the researchers confirmed that blocking PTP1B decreased the removal of the interferon receptor. As a result, interferon signaling became enhanced. Using human cells infected with hepatitis C, the researchers found that adding a PTP1B inhibitor allowed smaller doses of interferon to be effective in keeping the virus from reproducing. They demonstrated a similar effect in human cells infected with vesicular stomatitis virus.

Aiding in their work was the fact that pharmaceutical companies have already designed multiple drugs that inhibit the activity of PTP1B but for a completely separate reason than the enzyme's involvement in interferon signaling.

"PTP1B also works on the leptin receptor," Fuchs said. "This is the pathway that regulates satiety, appetite and weight gain. So in the past 10 years there have been massive industrial and academic undertaking to develop PTP1B inhibitors to treat obesity and diabetes."

To see how these PTP1B inhibitors would impact viral infections in a living organism, the researchers could not use mice because mice lack a portion of the receptor that PTP1B acts upon, and so blocking PTP1B does not impact interferon signaling in the same way as it does in humans and other mammals. Instead, they examined five cats that had been enrolled by their owners in the study. Each was suffering from chronic stomatitis, a condition that involves substantial inflammation in the mouth and makes it painful for the cats to eat and groom. The cats received a single injection of a PTP1B inhibitor. Two weeks later, all five showed noticeable reductions in redness and inflammation, providing clinical evidence that these drugs could be used to treat infection.

Fuchs said that what seemed like a drawback in the study that it couldn't be effectively modeled in mice ended up being a benefit, as naturally occurring diseases in animals such as cat and dogs more closely mimic many human diseases.

Because interferon is known to suppress tumors and help multiple sclerosis patients, the results of this study give the researchers optimism that PTP1B could be a target for anti-cancer and anti-autoimmune disease therapies.

As a next step, they plan to test the PTP1B inhibitors in a model of feline immunodeficiency virus, or the cat version of AIDS, to see if its virus-fighting capabilities can have an effect against that infection.


'/>"/>

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania
Source:Eurekalert

Related medicine news :

1. ADHD medicine affects the brains reward system
2. Capnography training video by BMC published in New England Journal of Medicine
3. Personalizing medicine: New American Chemical Society Prized Science video
4. Is your memory playing tricks on you? Check your medicine cabinet!
5. Midwest regenerative medicine symposium to be held in Cincinnati
6. Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley
7. Penn Medicines Daniel J. Rader, M.D., receives AHAs Clinical Research Prize
8. Penn Medicine contest maps 1,400 lifesaving AEDs via crowdsourcing contest fueled by smart phones
9. Penn Medicine expert wins AHAs Lifetime Achievement Award in Cardiac Resuscitation Science
10. Attention, parents: UC research reveals a secret about your medicine cabinet
11. Penn Medicine researchers map strategy for choosing wisely on low-value health care services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation Act (BCRA), ... Care Act (ACA), would result in 22 million Americans losing their health insurance by ... 20 million Americans have gained health insurance under the ACA, and from 2013 to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... ... ... Two residents from the Gardant-managed assisted living and memory care communities in ... to protect Medicaid funding. , The video, which was produced by the American Health ... and Cathy Schwarz, a couple who is still able to see each other every ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking for ... guidebook. This guidebook offers an excellent branding and exposure opportunity for the author ... and how-to’s that fall into the following categories:, ,     Media ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and ... offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
Breaking Medicine Technology: